TCON
Price:
$0.0322
Market Cap:
$109.72K
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I...[Read more]
Industry
Biotechnology
IPO Date
2015-01-30
Stock Exchange
NASDAQ
Ticker
TCON
According to TRACON Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -6160275.00. This represents a change of -370.22% compared to the average of 2.28M of the last 4 quarters.
The mean historical Enterprise Value of TRACON Pharmaceuticals, Inc. over the last ten years is 34.33M. The current -6160275.00 Enterprise Value has changed -1894.62% with respect to the historical average. Over the past ten years (40 quarters), TCON's Enterprise Value was at its highest in in the December 2020 quarter at 133.87M. The Enterprise Value was at its lowest in in the March 2018 quarter at -13852960.00.
Average
34.33M
Median
29.49M
Minimum
-3968738.00
Maximum
86.52M
Discovering the peaks and valleys of TRACON Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.71%
Maximum Annual Enterprise Value = 86.52M
Minimum Annual Increase = -2049.03%
Minimum Annual Enterprise Value = -3968738.00
Year | Enterprise Value | Change |
---|---|---|
2023 | -1887818.50 | -108.02% |
2022 | 23.54M | -6.23% |
2021 | 25.11M | -67.54% |
2020 | 77.35M | -2049.03% |
2019 | -3968738.00 | 129.02% |
2018 | -1732894.00 | -105.06% |
2017 | 34.28M | 1.18% |
2016 | 33.88M | -51.73% |
2015 | 70.18M | -18.89% |
2014 | 86.52M | 1.71% |
The current Enterprise Value of TRACON Pharmaceuticals, Inc. (TCON) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
15.59M
5-year avg
24.03M
10-year avg
34.33M
TRACON Pharmaceuticals, Inc.’s Enterprise Value is less than Rezolute, Inc. (246.85M), less than XOMA Corporation (295.03M), greater than Sio Gene Therapies Inc. (-61213000.00), less than Vincerx Pharma, Inc. (5.30M), less than Histogen Inc. (-4487565.00), less than Entera Bio Ltd. (73.28M), less than Tempest Therapeutics, Inc. (33.42M), less than Better Therapeutics, Inc. (7.71M), less than AN2 Therapeutics, Inc. (6.98M), less than Miromatrix Medical Inc. (90.06M), less than Inhibikase Therapeutics, Inc. (200.81M), less than PMV Pharmaceuticals, Inc. (40.78M), less than Anebulo Pharmaceuticals, Inc. (38.54M), less than Candel Therapeutics, Inc. (385.07M), less than Acurx Pharmaceuticals, Inc. (8.82M), less than Monopar Therapeutics Inc. (118.06M), less than Enochian Biosciences, Inc. (137.32M), less than Kronos Bio, Inc. (7.87M), less than Cyclerion Therapeutics, Inc. (5.97M), less than Larimar Therapeutics, Inc. (211.49M), less than Addex Therapeutics Ltd (7.35M), greater than Achilles Therapeutics plc (-35577954.00),
Company | Enterprise Value | Market cap |
---|---|---|
246.85M | $255.24M | |
295.03M | $318.13M | |
-61213000.00 | $0 | |
5.30M | $6.60M | |
-4487565.00 | $85.44K | |
73.28M | $79.89M | |
33.42M | $37.79M | |
7.71M | $5.45K | |
6.98M | $40.49M | |
90.06M | $92.95M | |
200.81M | $201.58M | |
40.78M | $76.33M | |
38.54M | $39.94M | |
385.07M | $385.61M | |
8.82M | $14.58M | |
118.06M | $124.08M | |
137.32M | $45.38M | |
7.87M | $57.03M | |
5.97M | $8.84M | |
211.49M | $241.20M | |
7.35M | $10.50M | |
-35577954.00 | $46.85M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TRACON Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like TRACON Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is TRACON Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for TRACON Pharmaceuticals, Inc. (TCON)?
What is the 3-year average Enterprise Value for TRACON Pharmaceuticals, Inc. (TCON)?
What is the 5-year average Enterprise Value for TRACON Pharmaceuticals, Inc. (TCON)?
How does the current Enterprise Value for TRACON Pharmaceuticals, Inc. (TCON) compare to its historical average?